SUGEN Appoints Gerald H. Moeller, Ph.D. and Samuel Hamad to Board of Directors.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--April 21, 1999-- SUGEN, Inc. (Nasdaq:SUGN) announced today the appointments of Gerald H. Moeller, Ph.D., and Samuel Hamad to its Board of Directors. Dr. Moeller was previously President and Chief Executive Officer of the Boehringer Mannheim Group. Following Boehringer Mannheim's acquisition by Hoffman La Roche in 1998, Dr. Moeller served as Head of Strategic Marketing and Global Development for Roche Pharma and a member of the Executive Committee of Hoffman La Roche. Mr. Hamad has held various senior management positions with Bristol-Myers Squibb Company, an international pharmaceutical company, including President of Bristol-Myers Squibb Europe and President, Bristol-Myers Squibb Intercontinental. Prior to joining Bristol-Myers Squibb Company, Mr. Hamad held senior management positions with Pfizer, Inc. and Merck & Company. "We are very pleased with the additions of Dr. Moeller and Mr. Hamad, as they bring valuable commercial experience and knowledge of the global pharmaceutical industry to our Board," said Stephen Evans-Freke, SUGEN Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . SUGEN, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule drugs, which target specific cellular signal transduction pathways. SUGEN currently has two cancer products in late stage clinical trials: SU101 (a PDGF PDGF platelet-derived growth factor; interacting with cell surface receptors and stimulating hydrolysis of inositol 1,4,5-triphosphate (IP3). receptor inhibitor) is in Phase III trials in refractory brain cancer, will be entering Phase III in refractory prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. this year, and is in Phase II in ovarian and non-small cell lung cancers; SU5416 (a Flk-1/KDR angiogenesis inhibitor angiogenesis inhibitor Oncology A chemotherapy adjuvant which inhibits the angiogenesis required for tumor growth and survive, especially for metastastatic tumors See CAI, CM101, IFN-alpha, IL-12, Marimastat, Pentosan polysulfate, Platelet factor 4, Thalidomide, TNP-470. ) is soon to be entering Phase III registrational studies for the treatment of non-small cell lung and colorectal cancer and Phase II/III in Kaposi's sarcoma. A third compound, SU6668, (a multi-mechanism inhibitor of angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. and tumor growth) is in Phase I for the treatment of solid tumors. The Company has major research and development collaborations with Zeneca, ASTA Medica medica (māˑ·dē·k , Allergan and Taiho. Additional written materials and press releases regarding SUGEN are available through the SUGEN Fax-On-Demand Information Service by dialing 1-888-329-4699 or at www.sugen.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion